The Food and Drug Administration declined to approve ivonescimab with chemotherapy for certain people with advanced lung cancer whose disease had progressed after targeted treatment, Summit Therapeutics said Sunday. A trial found the combination gave patients more time before their cancer worsened. The evidence that patients lived longer fell short of the threshold the FDA said it needed for approval, according to the company.
The application covered a specific group of people with locally advanced or metastatic non-small cell lung cancer and an alteration in a gene called EGFR. They had already received drugs that target EGFR. The decision leaves ivonescimab without FDA approval for that use.
What the trial found

The HARMONi trial, published in The Lancet Oncology, randomly assigned 438 people to one of two groups. Both received platinum-based chemotherapy. One group also received ivonescimab, while the other received a placebo. Participants had advanced, nonsquamous non-small cell lung cancer that had worsened after a newer class of EGFR-targeted drugs. The study ran at 114 cancer centers and hospitals across Asia, Europe and North America. Summit Therapeutics funded the trial.
The trial measured two outcomes separately. The first was progression-free survival, or how long people lived before their cancer worsened or they died. The median was 6.8 months with ivonescimab and chemotherapy, compared with 4.4 months in the comparison group. The researchers found the difference statistically significant. The median estimates the point by which half the patients in a group would have experienced progression or died. It describes a group outcome.
The other measure was overall survival, which counts how long people lived after entering the study. Researchers had a median of nearly 30 months of follow-up for that analysis. The reported survival medians were 16.8 months and 14.0 months, respectively. Despite that difference, the trial’s main analysis did not establish a statistically significant survival benefit. Serious side effects that researchers linked to treatment occurred in 61 of 218 patients who received the combination (28 percent) and 33 of 218 who received chemotherapy with placebo (15 percent).
Why the FDA declined the application
Summit said the FDA found that the improvement in time before progression, without a statistically significant gain in overall survival, was insufficient to show that the benefits outweighed the risks for this proposed use. Summit also reported a more favorable result from looking at survival data with longer follow-up. That later analysis was done after the planned analysis, and the FDA decision described by Summit came after the company had submitted additional survival data.
The FDA calls this type of decision a complete response letter. It tells a drugmaker that the agency has finished reviewing an application and cannot approve it in its current form. Summit says it will continue developing the drug. Its Sunday announcement did not give a date for a new application for this group of patients or indicate when the treatment might become available.
What the decision means for patients

The National Cancer Institute describes several approaches doctors may consider when non-small cell lung cancer returns or worsens. Which ones may be suitable depends in part on the cancer’s genetic findings and which treatments a patient has already received. Those details also affect who can join a study. The specific HARMONi trial record describes the study used in the application, and the published report says the study has finished enrolling.
For someone whose cancer has progressed after an EGFR-targeted drug, the practical next question is which approved treatments or currently enrolling studies match their cancer and treatment history. The published trial numbers describe outcomes for groups of patients, so an oncologist can help interpret what they mean for an individual case.









